For Medical Professionals
Through TauRx’s technology platform, the company is continuing to discover, assess and develop new compounds and biologics with therapeutic and diagnostic promise for neurodegenerative diseases caused by protein aggregation.
The company’s lead proprietary compound has completed Phase 3 clinical trials to evaluate its safety and efficacy in the treatment of Alzheimer’s disease and behavioural-variant frontotemporal dementia. Results from the most recent phase 3 study in Alzheimer's, LUCIDITY, will be available soon on completion of data analyses.